文献速递血栓与止血

ChAdOx1 nCov-19 静脉给药后血小板减少症与脾脏血小板导向的免疫反应

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration.
PubMed 文献 · Blood · 2022-01-01

本研究在27例确诊VITT患者中检出30%、26例疫苗接种后孤立性血小板减少症患者中检出42%存在靶向血小板糖蛋白受体的抗血小板抗体,提示广泛抗血小板自身免疫。小鼠实验显示静脉而非肌内注射ChAdOx1 nCov-19可触发血小板-腺病毒聚集体形成和血小板活化,聚集体被脾脏巨噬细胞吞噬后引发B细胞反应和循环抗血小板抗体。作者提出意外静脉注射可能是血小板导向自身免疫的潜在机制,预防静脉注射可能是针对疫苗接种后血小板相关病理的潜在措施。

要点

  • 确诊VITT患者中30%(n=27)检出靶向血小板糖蛋白受体的抗血小板抗体。
  • ChAdOx1 nCov-19接种后孤立性血小板减少症患者中42%(n=26)检出抗血小板抗体。
  • 小鼠静脉而非肌内注射ChAdOx1 nCov-19触发血小板-腺病毒聚集体形成和血小板活化。

核心结论

  • ChAdOx1 nCov-19给药后血小板相关并发症与血小板导向的自身免疫反应相关,意外静脉注射可能是其潜在机制。

研究设计与样本

  • 检测确诊VITT患者(n=27)和ChAdOx1 nCov-19接种后孤立性血小板减少症患者(n=26)的抗血小板抗体。
  • 采用体外和体内模型表征血小板导向自身免疫反应导致血小板减少的可能机制,小鼠实验比较静脉与肌内注射。

主要发现

  • 30%的确诊VITT患者(n=27)检出靶向血小板糖蛋白受体的抗血小板抗体。
  • 42%的ChAdOx1 nCov-19接种后孤立性血小板减少症患者(n=26)检出靶向血小板糖蛋白受体的抗血小板抗体。
  • 小鼠静脉而非肌内注射ChAdOx1 nCov-19触发血小板-腺病毒聚集体形成和血小板活化。
  • 静脉注射后聚集体被脾脏巨噬细胞吞噬,边缘区和滤泡中可见血小板残余,随后出现显著B细胞反应和循环抗血小板抗体。

临床怎么用

  • 作者提出,预防静脉注射可能是针对腺病毒载体疫苗接种后血小板相关病理的潜在措施。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them. Recently, a novel complication of SARS-CoV-2-targeted adenovirus vaccines has emerged: immune thrombocytopenia, either isolated, or accompanied by thrombosis (then termed VITT). This complication is characterized by low platelet counts, and in the case of VITT, also by platelet-activating platelet factor 4 antibodies reminiscent of heparin-induced thrombocytopenia, leading to a prothrombotic state with clot formation at unusual anatomic sites. Here, we detected antiplatelet antibodies targeting platelet glycoprotein receptors in 30% of patients with proven VITT (n = 27) and 42% of patients with isolated thrombocytopenia after ChAdOx1 nCov-19 vaccination (n = 26), indicating broad antiplatelet autoimmunity in these clinical entities. We use in vitro and in vivo models to characterize possible mechanisms of these platelet-targeted autoimmune responses leading to thrombocytopenia. We show that IV but not intramuscular injection of ChAdOx1 nCov-19 triggers platelet-adenovirus aggregate formation and platelet activation in mice. After IV injection, these aggregates are phagocytosed by macrophages in the spleen, and platelet remnants are found in the marginal zone and follicles. This is followed by a pronounced B-cell response with the emergence of circulating antibodies binding to platelets. Our work contributes to the understanding of platelet-associated complications after ChAdOx1 nCov-19 administration and highlights accidental IV injection as a potential mechanism of platelet-targeted autoimmunity. Hence, preventing IV injection when administering adenovirus-based vaccines could be a potential measure against platelet-associated pathologies after vaccination.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nicolai L, Leunig A, Pekayvaz K, et al. Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration. Blood. 2022. PMID: 35486845. doi:10.1182/blood.2021014712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。